|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||2.32 - 2.52|
|52-week range||2.21 - 8.61|
|PE ratio (TTM)||N/A|
|Earnings date||13 Feb 2018 - 19 Feb 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.00|
ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy, announced today preliminary, unaudited, revenue results for the fourth quarter and the year ended December 31, 2017.
ConforMIS iTotal Implant is designed to match each patient’s individual j-curves, based on their own unique anatomy. Each ConforMIS implant is accompanied with a detailed, patient-specific, pre-surgical iView plan for each individual case. ConforMIS CR Implant and iJig patient specific cutting guides are designed to achieve neutral mechanical axis alignment.
On a per-share basis, the Billerica, Massachusetts-based company said it had a loss of 29 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
The Zacks Analyst Blog Highlights: PRA Health Sciences, Mesa Laboratories, ConforMIS, Check-Cap and Streamline Health Solutions